share_log

Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE

Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE

Capricor Treateutics的股价正在上涨。该公司表示,在对其正在进行的第二阶段希望的开放标签延伸研究进行初步审查后,将提供最近发现的最新情况
Benzinga ·  2021/06/17 10:59

Capricor Therapeutics shares are trading higher. The company said it will provide an update on recent findings after a preliminary review of its ongoing open-label extension study of the Phase II HOPE-2 trial with lead asset, CAP-1002 at PPMD 2021.

Capricor Treateutics的股价正在上涨。该公司表示,在对其正在进行的第二阶段HOPE-2试验的开放标签扩展研究进行初步审查后,它将提供最近发现的最新情况。该试验采用Lead Asset,CAP-1002,PPMD 2021。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发